Published in Mult Scler Int on March 05, 2014
Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord (2016) 0.78
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Mult Scler Int (2016) 0.75
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med (1998) 4.65
Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol (2009) 2.50
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology (2010) 2.26
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain (2004) 1.70
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology (2010) 1.44
Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology (2012) 1.17
Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler (2004) 1.07
Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler (2011) 1.05
Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology (2011) 1.04
Pregnancy and multiple sclerosis. Mayo Clin Proc (1997) 1.03
The motherhood choice: themes arising in the decision-making process for women with multiple sclerosis. Mult Scler (2008) 1.00
Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler (2010) 0.93
Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler (2013) 0.93
Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord (2012) 0.93
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg (2012) 0.90
Safety first, efficacy second in disease modifying therapies. Mult Scler (2011) 0.80